{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:21:18Z","timestamp":1782246078444,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T00:00:00Z","timestamp":1296086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"DOI":"10.1038\/cddis.2010.96","type":"journal-article","created":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T11:27:30Z","timestamp":1296127650000},"page":"e117-e117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and \u03b1-tubulin hyperacetylation both in vitro and in vivo"],"prefix":"10.1038","volume":"2","author":[{"given":"Q-y","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-l","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-h","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q-j","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X-j","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z-g","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,27]]},"reference":[{"key":"BFcddis201096_CR1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature02625","volume":"429","author":"G Egger","year":"2004","unstructured":"Egger G, Liang G, Aparicio A, Jones PA . Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457\u2013463.","journal-title":"Nature"},{"key":"BFcddis201096_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrg816","volume":"3","author":"PA Jones","year":"2002","unstructured":"Jones PA, Baylin SB . The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415\u2013428.","journal-title":"Nat Rev Genet"},{"key":"BFcddis201096_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejphar.2009.10.011","volume":"625","author":"LS Kristensen","year":"2009","unstructured":"Kristensen LS, Nielsen HM, Hansen LL . Epigenetics and cancer treatment. Eur J Pharmacol 2009; 625: 131\u2013142.","journal-title":"Eur J Pharmacol"},{"key":"BFcddis201096_CR4","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"WK Kelly","year":"2005","unstructured":"Kelly WK, O\u2019Connor OA, Krug LM, Chiao JH, Heaney M, Curley T et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923\u20133931.","journal-title":"J Clin Oncol"},{"key":"BFcddis201096_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrd772","volume":"1","author":"RW Johnstone","year":"2002","unstructured":"Johnstone RW . Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287\u2013299.","journal-title":"Nat Rev Drug Discov"},{"key":"BFcddis201096_CR6","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","volume":"27","author":"AA Lane","year":"2009","unstructured":"Lane AA, Chabner BA . Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459\u20135468.","journal-title":"J Clin Oncol"},{"key":"BFcddis201096_CR7","doi-asserted-by":"publisher","first-page":"20436","DOI":"10.1074\/jbc.M000202200","volume":"275","author":"LJ Juan","year":"2000","unstructured":"Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000; 275: 20436\u201320443.","journal-title":"J Biol Chem"},{"key":"BFcddis201096_CR8","doi-asserted-by":"publisher","first-page":"38879","DOI":"10.1074\/jbc.M505733200","volume":"280","author":"CS Chen","year":"2005","unstructured":"Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS . Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 2005; 280: 38879\u201338887.","journal-title":"J Biol Chem"},{"key":"BFcddis201096_CR9","doi-asserted-by":"publisher","first-page":"7852","DOI":"10.1158\/0008-5472.CAN-04-1552","volume":"64","author":"SM Kurinna","year":"2004","unstructured":"Kurinna SM, Tsao CC, Nica AF, Jiffar T, Ruvolo PP . Ceramide promotes apoptosis in lung cancer-derived A549 cells by a mechanism involving c-Jun NH2-terminal kinase. Cancer Res 2004; 64: 7852\u20137856.","journal-title":"Cancer Res"},{"key":"BFcddis201096_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrc1411","volume":"4","author":"B Ogretmen","year":"2004","unstructured":"Ogretmen B, Hannun YA . Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4: 604\u2013616.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis201096_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/0092-8674(95)90429-8","volume":"82","author":"R Bose","year":"1995","unstructured":"Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R . Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1995; 82: 405\u2013414.","journal-title":"Cell"},{"issue":"Part 3","key":"BFcddis201096_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1042\/bj3350465","volume":"335","author":"S Mathias","year":"1998","unstructured":"Mathias S, Pena LA, Kolesnick RN . Signal transduction of stress via ceramide. Biochem J 1998; 335 (Part 3): 465\u2013480.","journal-title":"Biochem J"},{"key":"BFcddis201096_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0145-2126(99)00048-X","volume":"23","author":"D Myrick","year":"1999","unstructured":"Myrick D, Blackinton D, Klostergaard J, Kouttab N, Maizel A, Wanebo H et al. Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide. Leuk Res 1999; 23: 569\u2013578.","journal-title":"Leuk Res"},{"key":"BFcddis201096_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s002800000140","volume":"46","author":"S Mehta","year":"2000","unstructured":"Mehta S, Blackinton D, Omar I, Kouttab N, Myrick D, Klostergaard J et al. Combined cytotoxic action of paclitaxel and ceramide against the human Tu138 head and neck squamous carcinoma cell line. Cancer Chemother Pharmacol 2000; 46: 85\u201392.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFcddis201096_CR15","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s11095-008-9614-3","volume":"25","author":"D Deshpande","year":"2008","unstructured":"Deshpande D, Devalapally H, Amiji M . Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Pharm Res 2008; 25: 1936\u20131947.","journal-title":"Pharm Res"},{"key":"BFcddis201096_CR16","first-page":"907","volume":"16","author":"L Qiu","year":"2006","unstructured":"Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S et al. Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells. Oncol Rep 2006; 16: 907\u2013913.","journal-title":"Oncol Rep"},{"key":"BFcddis201096_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ijc.10699","volume":"103","author":"Y Yamashita","year":"2003","unstructured":"Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S et al. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest\/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 2003; 103: 572\u2013576.","journal-title":"Int J Cancer"},{"key":"BFcddis201096_CR18","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1158\/0008-5472.CAN-04-2440","volume":"65","author":"M Rahmani","year":"2005","unstructured":"Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1\/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65: 2422\u20132432.","journal-title":"Cancer Res"},{"key":"BFcddis201096_CR19","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1016\/j.febslet.2006.07.071","volume":"580","author":"S Elojeimy","year":"2006","unstructured":"Elojeimy S, Holman DH, Liu X, El-Zawahry A, Villani M, Cheng JC et al. New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett 2006; 580: 4751\u20134756.","journal-title":"FEBS Lett"},{"issue":"Part 2","key":"BFcddis201096_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1042\/bj3310563","volume":"331","author":"RJ Veldman","year":"1998","unstructured":"Veldman RJ, Klappe K, Hoekstra D, Kok JW . Metabolism and apoptotic properties of elevated ceramide in HT29rev cells. Biochem J 1998; 331 (Part 2): 563\u2013569.","journal-title":"Biochem J"},{"key":"BFcddis201096_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1046\/j.1432-1327.1998.2580233.x","volume":"258","author":"T Babia","year":"1998","unstructured":"Babia T, Veldman RJ, Hoekstra D, Kok JW . Modulation of carcinoembryonic antigen release by glucosylceramide\u2014implications for HT29 cell differentiation. Eur J Biochem 1998; 258: 233\u2013242.","journal-title":"Eur J Biochem"},{"key":"BFcddis201096_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1023\/B:GLYC.0000033627.02765.cc","volume":"20","author":"G Tettamanti","year":"2004","unstructured":"Tettamanti G . Ganglioside\/glycosphingolipid turnover: new concepts. Glycoconj J 2004; 20: 301\u2013317.","journal-title":"Glycoconj J"},{"key":"BFcddis201096_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.canlet.2003.08.034","volume":"206","author":"CP Reynolds","year":"2004","unstructured":"Reynolds CP, Maurer BJ, Kolesnick RN . Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004; 206: 169\u2013180.","journal-title":"Cancer Lett"},{"key":"BFcddis201096_CR24","first-page":"942","volume":"6","author":"H Sietsma","year":"2000","unstructured":"Sietsma H, Veldman RJ, Kolk D, Ausema B, Nijhof W, Kamps W et al. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin Cancer Res 2000; 6: 942\u2013948.","journal-title":"Clin Cancer Res"},{"key":"BFcddis201096_CR25","first-page":"183","volume":"26","author":"NS Radin","year":"1993","unstructured":"Radin NS, Shayman JA, Inokuchi J . Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances. Adv Lipid Res 1993; 26: 183\u2013213.","journal-title":"Adv Lipid Res"},{"key":"BFcddis201096_CR26","doi-asserted-by":"crossref","first-page":"15523","DOI":"10.1016\/S0021-9258(18)82288-8","volume":"268","author":"RT Dobrowsky","year":"1993","unstructured":"Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA . Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 1993; 268: 15523\u201315530.","journal-title":"J Biol Chem"},{"key":"BFcddis201096_CR27","doi-asserted-by":"publisher","first-page":"12808","DOI":"10.1074\/jbc.270.21.12808","volume":"270","author":"B Law","year":"1995","unstructured":"Law B, Rossie S . The dimeric and catalytic subunit forms of protein phosphatase 2A from rat brain are stimulated by C2-ceramide. J Biol Chem 1995; 270: 12808\u201312813.","journal-title":"J Biol Chem"},{"key":"BFcddis201096_CR28","doi-asserted-by":"crossref","first-page":"19605","DOI":"10.1016\/S0021-9258(17)32212-3","volume":"269","author":"RA Wolff","year":"1994","unstructured":"Wolff RA, Dobrowsky RT, Bielawska A, Obeid LM, Hannun YA . Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J Biol Chem 1994; 269: 19605\u201319609.","journal-title":"J Biol Chem"},{"key":"BFcddis201096_CR29","doi-asserted-by":"publisher","first-page":"21335","DOI":"10.1074\/jbc.274.30.21335","volume":"274","author":"K Kishikawa","year":"1999","unstructured":"Kishikawa K, Chalfant CE, Perry DK, Bielawska A, Hannun YA . Phosphatidic acid is a potent and selective inhibitor of protein phosphatase 1 and an inhibitor of ceramide-mediated responses. J Biol Chem 1999; 274: 21335\u201321341.","journal-title":"J Biol Chem"},{"key":"BFcddis201096_CR30","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1158\/1535-7163.MCT-06-0209","volume":"5","author":"SC Dowdy","year":"2006","unstructured":"Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006; 5: 2767\u20132776.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis201096_CR31","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1158\/0008-5472.CAN-04-3757","volume":"65","author":"AI Marcus","year":"2005","unstructured":"Marcus AI, Zhou J, O\u2019Brate A, Hamel E, Wong J, Nivens M et al. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 2005; 65: 3883\u20133893.","journal-title":"Cancer Res"},{"key":"BFcddis201096_CR32","first-page":"937","volume":"1","author":"MV Blagosklonny","year":"2002","unstructured":"Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002; 1: 937\u2013941.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis201096_CR33","doi-asserted-by":"publisher","first-page":"7685","DOI":"10.1074\/jbc.M310997200","volume":"279","author":"MH Brush","year":"2004","unstructured":"Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S . Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem 2004; 279: 7685\u20137691.","journal-title":"J Biol Chem"},{"key":"BFcddis201096_CR34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/417455a","volume":"417","author":"C Hubbert","year":"2002","unstructured":"Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417: 455\u2013458.","journal-title":"Nature"},{"key":"BFcddis201096_CR35","doi-asserted-by":"publisher","first-page":"12735","DOI":"10.1074\/jbc.M111011200","volume":"277","author":"Y Lim","year":"2002","unstructured":"Lim Y, Han I, Kwon HJ, Oh ES . Trichostatin A-induced detransformation correlates with decreased focal adhesion kinase phosphorylation at tyrosine 861 in ras-transformed fibroblasts. J Biol Chem 2002; 277: 12735\u201312740.","journal-title":"J Biol Chem"},{"key":"BFcddis201096_CR36","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1093\/emboj\/cdf682","volume":"21","author":"A Matsuyama","year":"2002","unstructured":"Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002; 21: 6820\u20136831.","journal-title":"EMBO J"},{"key":"BFcddis201096_CR37","doi-asserted-by":"publisher","first-page":"21901","DOI":"10.1074\/jbc.273.34.21901","volume":"273","author":"H Liao","year":"1998","unstructured":"Liao H, Li Y, Brautigan DL, Gundersen GG . Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau. J Biol Chem 1998; 273: 21901\u201321908.","journal-title":"J Biol Chem"},{"key":"BFcddis201096_CR38","first-page":"280","volume":"16","author":"RJ Metz","year":"1996","unstructured":"Metz RJ, Vellody K, Patel S, Bergstrom R, Meisinger J, Jackson J et al. Vitamin D3 and ceramide reduce the invasion of tumor cells through extracellular matrix components by elevating protein phosphatase-2A. Invasion Metastasis 1996; 16: 280\u2013290.","journal-title":"Invasion Metastasis"},{"key":"BFcddis201096_CR39","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.bbamcr.2008.06.001","volume":"1783","author":"R Debret","year":"2008","unstructured":"Debret R, Brassart-Pasco S, Lorin J, Martoriati A, Deshorgue A, Maquart FX et al. Ceramide inhibition of MMP-2 expression and human cancer bronchial cell invasiveness involve decreased histone acetylation. Biochim Biophys Acta 2008; 1783: 1718\u20131727.","journal-title":"Biochim Biophys Acta"},{"key":"BFcddis201096_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1042\/BJ20060678","volume":"399","author":"M Gallego","year":"2006","unstructured":"Gallego M, Kang H, Virshup DM . Protein phosphatase 1 regulates the stability of the circadian protein PER2. Biochem J 2006; 399: 169\u2013175.","journal-title":"Biochem J"}],"container-title":["Cell Death & Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cddis201096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cddis201096","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis201096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:47:51Z","timestamp":1672962471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis201096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1]]}},"alternative-id":["BFcddis201096"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2010.96","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,27]]},"assertion":[{"value":"2 September 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}